{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:37Z","timestamp":1794047497798,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients with severe hemophilia A (HA) often develop undesired immune responses to therapeutic factor VIII (FVIII) that hamper replacement therapy with FVIII-derived products. The transplacental delivery of two Fc-fused FVIII domains in pregnant HA mice was shown to induce partial FVIII-specific immune tolerance in the offspring. Here, we evaluated whether the transplacental delivery of Fc-fused FVIII (rFVIIIFc) induces complete immune tolerance towards FVIII. rFVIIIFc injected to pregnant HA mice was poorly transferred to the fetal circulation and failed to confer tolerance to exogenous FVIII in the offspring. The poor transplacental delivery of rFVIIIFc was associated with the large size of the molecule and with the presence of positive patches at the surface of FVIII. It was, however, independent from the capacity of rFVIIIFc to bind Fcg receptors or von Willebrand factor in the maternal circulation. Conversely, the transplacental delivery of Fc-fused A2 and C2 immunodominant domains of FVIII, as well as of Fc-fused molecules containing seven different immunodominant FVIII-derived peptides decreased the levels of anti-FVIII antibodies following FVIII replacement therapy in the offspring. Our study paves the way towards the development of engineered Fc-fused molecules able to efficiently cross the placenta and confer potent and long-lasting immune tolerance to protein therapeutics.<\/jats:p>","DOI":"10.3324\/haematol.2024.287057","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:41:37Z","timestamp":1741840897000},"page":"2320-2331","source":"Crossref","is-referenced-by-count":0,"title":["Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptides"],"prefix":"10.3324","volume":"110","author":[{"given":"Alejandra","family":"Reyes-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Delignat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Daventure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Mimoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Georgescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"80016","doi-asserted-by":"crossref","unstructured":"Abdiche YN, Yeung YA, Chaparro-Riggers J. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs. 2015; 7(2):331-343.","DOI":"10.1080\/19420862.2015.1008353"},{"key":"80017","doi-asserted-by":"crossref","unstructured":"Martin WL, West AP, Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn\/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001; 7(4):867-877.","DOI":"10.1016\/S1097-2765(01)00230-1"},{"key":"80018","doi-asserted-by":"crossref","unstructured":"Oganesyan V, Damschroder MM, Cook KE. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem. 2014; 289(11):7812-7824.","DOI":"10.1074\/jbc.M113.537563"},{"key":"80019","doi-asserted-by":"crossref","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023; 23(7):415-432.","DOI":"10.1038\/s41577-022-00821-1"},{"key":"80020","doi-asserted-by":"crossref","unstructured":"Kayatani AKK, Leke RGF, Leke RIJ, Fogako J, Taylor DW. Transplacental transfer of total immunoglobulin G and antibodies to Plasmodium falciparum antigens between the 24th week of gestation and term. Sci Rep. 2022; 12(1):18864.","DOI":"10.1038\/s41598-022-21908-8"},{"key":"80021","doi-asserted-by":"crossref","unstructured":"Appleby P, Catty D. Transmission of immunoglobulin to foetal and neonatal mice. J Reprod Immunol. 1983; 5(4):203-213.","DOI":"10.1016\/0165-0378(83)90236-X"},{"key":"80022","doi-asserted-by":"crossref","unstructured":"Liu J, Deng Y, Wang A. Investigation into the role of the MITA-TRIM38 interaction in regulating pyroptosis and maintaining immune tolerance at the maternal-fetal interface. Cell Death Dis. 2023; 14(11):780.","DOI":"10.1038\/s41419-023-06314-w"},{"key":"80023","doi-asserted-by":"crossref","unstructured":"Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953; 172(4379):603-606.","DOI":"10.1038\/172603a0"},{"key":"80024","doi-asserted-by":"crossref","unstructured":"Culina S, Gupta N, Boisgard R. Materno-fetal transfer of preproinsulin through the neonatal Fc receptor prevents autoimmune diabetes. Diabetes. 2015; 64(10):3532-3542.","DOI":"10.2337\/db15-0024"},{"key":"80025","doi-asserted-by":"crossref","unstructured":"Gupta N, Culina S, Meslier Y. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Sci Transl Med. 2015; 7(275):275.","DOI":"10.1126\/scitranslmed.aaa1957"},{"key":"80026","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26(Suppl 6):1-158.","DOI":"10.1111\/hae.14046"},{"key":"80027","doi-asserted-by":"crossref","unstructured":"Gouw SC, Van Der Bom JG, Ljung R. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013; 368(3):231-239.","DOI":"10.1056\/NEJMoa1208024"},{"key":"80028","doi-asserted-by":"crossref","unstructured":"Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood. 2000; 96(5):1698-1702.","DOI":"10.1182\/blood.V96.5.1698"},{"key":"80029","doi-asserted-by":"crossref","unstructured":"Hay CRM, DiMichele DM, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119(6):1335-1344.","DOI":"10.1182\/blood-2011-08-369132"},{"key":"80030","doi-asserted-by":"crossref","unstructured":"Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. Aglycosylated immunoglobulin G 1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A. 2008; 105(51):20167-20172.","DOI":"10.1073\/pnas.0809257105"},{"key":"80031","doi-asserted-by":"crossref","unstructured":"Leyte A, Van Schijndel HB, Niehrs C. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem. 1991; 266(2):740-746.","DOI":"10.1016\/S0021-9258(17)35234-1"},{"key":"80032","doi-asserted-by":"crossref","unstructured":"Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995; 10(1):119-121.","DOI":"10.1038\/ng0595-119"},{"key":"80033","unstructured":"Mitruka BM, Rawnsley HM. Clinical biochemical and hematological reference values in normal experimental animals and normal humans. 1977."},{"key":"80034","unstructured":"Harkness JE, Wagner JE. The Biology and Medicine of Rabbits and Rodents. 5th ed. 2010."},{"key":"80035","doi-asserted-by":"crossref","unstructured":"Kulandavelu S, Qu D, Sunn N. Embryonic and neonatal phenotyping of genetically engineered mice. ILAR J. 2006; 47(2):103-117.","DOI":"10.1093\/ilar.47.2.103"},{"key":"80036","doi-asserted-by":"crossref","unstructured":"Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016; 128(16):2007-2016.","DOI":"10.1182\/blood-2016-04-713289"},{"key":"80037","doi-asserted-by":"crossref","unstructured":"Boswell CA, Tesar DB, Mukhyala K, Theil F-P, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010; 21(12):2153-2163.","DOI":"10.1021\/bc100261d"},{"key":"80038","doi-asserted-by":"crossref","unstructured":"Gangadharan B, Ing M, Delignat S. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. Haematologica. 2017; 102(2):271-281.","DOI":"10.3324\/haematol.2016.148502"},{"key":"80039","doi-asserted-by":"crossref","unstructured":"Wroblewska A, van Haren SD, Herczenik E. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood. 2012; 119(22):5294-5300.","DOI":"10.1182\/blood-2011-11-391680"},{"key":"80040","doi-asserted-by":"crossref","unstructured":"Delignat S, Rayes J, Dasgupta S. Removal of mannose-ending glycan at Asn2118 abrogates FVIII presentation by human monocyte-derived dendritic cells. Front Immunol. 2020; 11:393.","DOI":"10.3389\/fimmu.2020.00393"},{"key":"80041","doi-asserted-by":"crossref","unstructured":"Steinitz KN, Van Helden PM, Binder B. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood. 2012; 119(17):4073-4082.","DOI":"10.1182\/blood-2011-08-374645"},{"key":"80042","doi-asserted-by":"crossref","unstructured":"Schellenberger V, Wang C, Geething NC. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009; 27(12):1186-1190.","DOI":"10.1038\/nbt.1588"},{"key":"80043","doi-asserted-by":"crossref","unstructured":"Butenas S, Parhami-Seren B, Undas A, Fass DN, Mann KG. The \u201cnormal\u201d factor VIII concentration in plasma. Thrombo Res. 2010; 126(2):119-123.","DOI":"10.1016\/j.thromres.2010.04.004"},{"key":"80044","doi-asserted-by":"crossref","unstructured":"Mimoun A, Bou-Jaoudeh M, Delignat S. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy. J Thromb Haemost. 2023; 21(9):2405-2417.","DOI":"10.1016\/j.jtha.2023.05.021"},{"key":"80045","doi-asserted-by":"crossref","unstructured":"Sakurai F, Iizuka S, Tsukamoto T. Transplacental delivery of factor IX Fc-fusion protein ameliorates bleeding phenotype of newborn hemophilia B mice. J Control Release. 2024; 374:415-424.","DOI":"10.1016\/j.jconrel.2024.08.022"},{"key":"80046","doi-asserted-by":"crossref","unstructured":"Jacquemin MG, Desqueper BG, Benhida A. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998; 92(2):496-506.","DOI":"10.1182\/blood.V92.2.496"},{"key":"80047","doi-asserted-by":"crossref","unstructured":"van den Brink EN, Turenhout EA, Bovenschen N. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII. Blood. 2001; 97(4):966-972.","DOI":"10.1182\/blood.V97.4.966"},{"key":"80048","doi-asserted-by":"crossref","unstructured":"Hsu T-C, Pratt KP, Thompson AR. The factor VIII C1 domain contributes to platelet binding. Blood. 2008; 111(1):200-208.","DOI":"10.1182\/blood-2007-01-068957"},{"key":"80049","doi-asserted-by":"crossref","unstructured":"Grevys A, Frick R, Mester S. Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. iScience. 2022; 25(2):103746.","DOI":"10.1016\/j.isci.2022.103746"},{"key":"80050","doi-asserted-by":"crossref","unstructured":"Schoch A, Kettenberger H, Mundigl O. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015; 112(19):5997-6002.","DOI":"10.1073\/pnas.1408766112"},{"key":"80051","doi-asserted-by":"crossref","unstructured":"Spiegel PC, Jacquemin M, Saint-Remy J-MR, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain\u2013immunoglobulin G4\u03ba Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood. 2001; 98(1):13-19.","DOI":"10.1182\/blood.V98.1.13"},{"key":"80052","doi-asserted-by":"crossref","unstructured":"Von Drygalski A, Chowdary P, Kulkarni R. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023; 388(4):310-318.","DOI":"10.1056\/NEJMoa2209226"},{"key":"80053","doi-asserted-by":"crossref","unstructured":"Chhabra ES, Liu T, Kulman J. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020; 135(17):1484-1496.","DOI":"10.1182\/blood.2019001292"},{"key":"80054","doi-asserted-by":"crossref","unstructured":"Konkle BA, Shapiro AD, Quon DV. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med. 2020; 383(11):1018-1027.","DOI":"10.1056\/NEJMoa2002699"},{"key":"80055","doi-asserted-by":"crossref","unstructured":"Fuller JR, Knockenhauer KE, Leksa NC, Peters RT, Batchelor JD. Molecular determinants of the factor VIII\/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy. Blood. 2021; 137(21):2970-2980.","DOI":"10.1182\/blood.2020009197"},{"key":"80056","doi-asserted-by":"crossref","unstructured":"Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest. 1989; 83(6):1978-1984.","DOI":"10.1172\/JCI114107"},{"key":"80057","doi-asserted-by":"crossref","unstructured":"Markovitz RC, Healey JF, Parker ET, Meeks SL, Lollar P. The diversity of the immune response to the A2 domain of human factor VIII. Blood. 2013; 121(14):2785-2795.","DOI":"10.1182\/blood-2012-09-456582"},{"key":"80058","doi-asserted-by":"crossref","unstructured":"Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood. 2007; 110(13):4234-4242.","DOI":"10.1182\/blood-2007-06-096842"},{"key":"80059","doi-asserted-by":"crossref","unstructured":"Prescott R, Nakai H, Saenko EL. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood. 1997; 89(10):3663-3671.","DOI":"10.1182\/blood.V89.10.3663.3663_3663_3671"},{"key":"80060","doi-asserted-by":"crossref","unstructured":"Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol. 2002; 32(11):3305-3314.","DOI":"10.1002\/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J"},{"key":"80061","doi-asserted-by":"crossref","unstructured":"Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev. 2009; 61(11):965-976.","DOI":"10.1016\/j.addr.2009.07.001"},{"key":"80062","doi-asserted-by":"crossref","unstructured":"Musunuri S, Weidenbacher PAB, Kim PS. Bringing immunofocusing into focus. NPJ Vaccines. 2024; 9(1):11.","DOI":"10.1038\/s41541-023-00792-x"},{"key":"80063","doi-asserted-by":"crossref","unstructured":"Porcheddu V, Lhomme G, Giraudet R, Correia E, Maill\u00e8re B. The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes. Front Immunol. 2024; 15:1345195.","DOI":"10.3389\/fimmu.2024.1345195"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11978\/78183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11978\/78870","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11978\/78183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:21Z","timestamp":1794046101000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.287057","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}